Core Insights - ICU Medical reported fourth-quarter 2025 revenue of $536 million, achieving 2% organic growth and 5% organic growth for the full year, with record performance in consumables and infusion systems [4][7] - The company delivered adjusted EBITDA of $98 million and adjusted earnings per share of $1.91, with gross margins remaining above 40% [3][7] - The 2026 outlook anticipates low- to mid-single-digit organic growth, adjusted EBITDA of $400–430 million, and adjusted EPS of $7.75–8.45, with a focus on improving free cash flow to reduce debt [5][15] Financial Performance - Adjusted SG&A expenses were reported at $113 million, and adjusted R&D expenses were $21 million, totaling adjusted operating expenses of $134 million, which is 25% of revenue [1] - The adjusted gross margin for the quarter was 40.5%, consistent with prior guidance of 40% to 41%, impacted by $11 million in tariff expenses [2][7] - Adjusted EBITDA declined 7% year-over-year from $106 million, primarily due to the deconsolidation of IV Solutions and tariff impacts, representing a $25 million EBITDA headwind [7] Business Segments - Consumables revenue grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic, driven by strong demand in infusion consumables and oncology [8] - Infusion systems revenue increased 3% reported and 1% organic in Q4, with expectations of mid-single-digit organic growth in the near term [16] - Vital Care experienced a 6% organic decline and a 35% reported decline due to the IV Solutions deconsolidation, with management focusing on discontinuing loss-making SKUs [16] Regulatory and Integration Updates - The company closed a broad FDA warning letter related to Smiths Medical and completed major manufacturing and ERP integrations, which are expected to unlock synergies [6][11] - ICU Medical is pursuing 510(k) clearances for key products, including the Medfusion 5000 syringe pump and LifeShield software, as part of its strategy to enhance product offerings [10] 2026 Guidance and Strategic Focus - The company projects full-year adjusted gross margin of around 41%, with improvements expected throughout the year, despite manufacturing inflation and tariff expenses [14] - Free cash flow is expected to improve in 2026, with a focus on debt reduction and a long-term leverage target of 2x by early 2027 [18] - Management indicated that any strategic moves would need to avoid value destruction, particularly in the Critical Care segment, which is seen as less synergistic [19]